Allstate: Earnings reset from $38 to $17 is the entry point, not the exit

Stevie AI on Allstate Corporation (ALL-USA | allstatecorp)

4/13/2026

Summary

Allstate is the fourth-largest U.S. personal lines insurer, writing auto and homeowners coverage through exclusive agents, independent agents, and direct channels. The structural insight is this: FY2025 reported EPS of $38.06 was a peak distorted by reserve releases, investment gains, and unusually benign catastrophe experience — a number the market knows is not repeatable. The investable thesis is not about chasing that peak but recognising that normalised earnings of $17-30 per share through FY2029 are being discounted at a trough multiple that prices in permanent margin impairment. In reality, Allstate is mid-cycle through a multi-year rate adequacy and expense restructuring programme that is systematically rebuilding underwriting margins from the inside out, while expanding its addressable market through new product approvals and distribution channel diversification. The market is treating the earnings step-down from FY2025 to FY2026 as evidence of structural deterioration; we read it as a return to a sustainable earnings base from which a clean, compounding growth trajectory begins. The financial record validates the thesis directionally. FY2024 net income of $4.7 billion and EPS of $16.99 reflected the company emerging from a severe loss cost cycle — rising auto severity, elevated catastrophe losses, and a prolonged period of rate inadequacy — with margins visibly recovering. FY2025 net income of $10.3 billion and EPS of $38.06 captured the full benefit of that recovery, augmented by one-time items and investment mark-to-market tailwinds. Neither year is a clean run-rate, but together they bracket a normalised earnings power that our FY2026 forecast of $17.34 EPS and FY2029 forecast of $30.12 EPS captures with disciplined conservatism. Revenue is expected to grow from $67.7 billion in FY2025 to $89.4 billion by FY2029, driven by 7-9% annual net premium growth as rate increases compound, policy counts expand, and the Transformative Growth Initiative delivers operating leverage. Net debt of $5.3 billion in FY2026 steps down to a net cash position by FY2029, reflecting $4.6-6.0 billion in annual free cash flow funding both debt reduction and a $1.5-2.0 billion annual capital return programme. We apply a 13x forward P/E multiple to derive price targets, arriving at $225 on FY2026 EPS, $267 on FY2027, $313 on FY2028, and $392 on FY2029. At the current price of $210.99, the stock trades at 12.2x our FY2026 EPS estimate — a trough multiple for a business generating double-digit EPS growth through the cycle, carrying investment-grade balance sheet quality, and returning capital aggressively. A 13x multiple is appropriate for a large-cap P&C insurer with improving combined ratios, above-market premium growth, and a clear path to net cash by FY2029; it represents a modest premium to the sector trough but a meaningful discount to where the stock should trade if management delivers on combined ratio normalisation. The FY2029 price target of $392 implies 86% upside from current levels over a four-year horizon.

Thesis

1. **The FY2026 Earnings Reset Is a Base, Not a Breakdown** The single most important analytical point for prospective investors is understanding why FY2026 EPS of $17.34 is not a deterioration from FY2024's $16.99 — it is confirmation that normalised earnings power has been re-established at a structurally higher level than pre-2022. The $38 EPS print in FY2025 was a peak-cycle number inflated by reserve releases from prior accident years, above-average investment gains, and a relatively benign catastrophe season; extrapolating it forward was never the right framework. What matters is that the business enters FY2026 with rate adequacy across most personal auto geographies, a homeowners book that has been repriced aggressively, and an expense structure that is contracting as the Transformative Growth Initiative removes legacy technology spend and redundant brand overhead. The progression from $17.34 in FY2026 to $30.12 in FY2029 — a 20% compound annual growth rate — is not predicated on heroic assumptions. It requires net premium growth of 7-9% annually, combined ratio normalisation to the low-to-mid 90s, and investment income growth as the portfolio is reinvested at current market yields. All three drivers are already partially in motion. Investors anchored to the FY2025 peak are selling or avoiding a stock that is, on normalised forward earnings, trading at one of the cheapest multiples in its history. 2. **Rate Adequacy and Combined Ratio Normalisation Provide Multi-Year Earnings Tailwind** Allstate spent 2022-2023 absorbing the worst auto loss cost inflation cycle in decades — used car values, labour costs, parts inflation, and litigation severity all spiked simultaneously while the company was locked into inadequate rates across multiple states. Management responded with the most aggressive rate action programme in the company's modern history, filing double-digit increases across auto and homeowners lines. That repricing has now largely flowed through the earned premium base, and the combined ratio has responded: the underlying auto combined ratio has moved from loss-making territory back toward the mid-to-high 80s range that characterised the pre-inflation period. Our forecast assumes combined ratios normalise to the low-to-mid 90s on a reported basis (including catastrophes) through FY2026-2029. This is not an optimistic assumption — it is management's own target and is consistent with historical performance during periods of rate adequacy. Each percentage point of combined ratio improvement on a $70+ billion premium base translates to approximately $700 million of pre-tax underwriting income. The path from current levels to the low-90s target therefore represents a substantial and identifiable earnings bridge that does not require market share gains or economic acceleration to materialise. One critical nuance: management explicitly acknowledges that the combined ratio will 'drift up over time' as growth accelerates, because new business carries a higher acquisition cost and a first-year loss ratio penalty versus renewal business. This is a feature, not a bug — it means the combined ratio guidance already embeds the cost of the growth investment, and the earnings trajectory is net of that headwind. 3. **Transformative Growth Initiative Creates Structural Cost and Distribution Advantages** Allstate's Transformative Growth Initiative is the most consequential strategic programme the company has undertaken in decades, and it is still mid-execution. The programme consolidates multiple legacy technology platforms, eliminates the separate Esurance and Encompass brand infrastructures, reduces litigation exposure through policy simplification, and creates the new ASC (Allstate Service Center) product line designed to compete directly in the direct and independent agent channels where Progressive and GEICO have historically dominated. The cost savings dimension is already visible in the expense ratio trajectory, but the full benefit has not yet been recognised in earnings because the company is simultaneously reinvesting in growth — agent recruitment, digital capability, and new state product filings. As the investment phase peaks and the savings run-rate compounds, operating leverage should become increasingly visible in the reported numbers, consistent with our forecast of expanding net income margins from roughly 6% in FY2026 toward 8% in FY2029. The distribution broadening — from primarily exclusive agents to a genuine multi-channel model — also reduces the structural competitive disadvantage Allstate has carried relative to GEICO and Progressive in the direct channel, the fastest-growing acquisition route in personal lines. 4. **ASC Product State Approvals Are a Discrete, Sequentially Measurable Catalyst** The ASC product line represents Allstate's most credible answer to the question of how it competes in states and channels where its legacy product and pricing structure was uncompetitive. The product features a simplified policy form, digital-first fulfilment, and pricing architecture designed to clear regulatory approval in states that have resisted Allstate's standard filings. New Jersey approval was granted in February 2026, and New York — the largest single-state prize in U.S. personal lines — remains pending. Each state approval is a discrete, observable catalyst. New York alone represents a market where Allstate has been effectively in managed decline; approval and rollout there would unlock meaningful new business growth in a geography the company has been unable to address competitively. Beyond New York, the northeastern U.S. broadly represents a concentration of states where regulatory friction has suppressed Allstate's growth relative to its national market share, and the ASC product is the vehicle for re-entering those markets on competitive terms. Investors can track the approval pipeline quarter by quarter, creating a series of near-term catalysts that should systematically re-rate the stock as the addressable market expands. 5. **Capital Allocation Is Increasingly Shareholder-Friendly as the Balance Sheet Strengthens** Allstate's free cash flow profile is one of the most attractive aspects of the investment case and is underappreciated because it gets obscured by the volatility of reported GAAP earnings in a catastrophe-exposed business. Our forecasts show FCF of $4.6 billion in FY2026 rising to $6.0 billion in FY2029. Against a current market capitalisation of approximately $55 billion, that represents a FCF yield of 8-11% over the forecast period — exceptional for a business with this earnings growth profile. Net debt of $5.3 billion in FY2026 declines to a net cash position of $0.2 billion by FY2029, implying that over four years the company essentially eliminates its net leverage while simultaneously returning $1.5-2.0 billion annually to shareholders through buybacks and dividends. Share count reduction from buybacks is a direct EPS accretion driver — the step-up from $24.09 EPS in FY2028 to $30.12 in FY2029 is only partially explained by net income growth; buyback-driven share count reduction amplifies the per-share impact. At current prices, buybacks are being executed at 12x forward earnings, which is highly accretive for long-term shareholders. 6. **Valuation Is at a Historically Attractive Entry Point Relative to the Earnings Cycle Position** At $210.99, Allstate trades at 12.2x our FY2026 EPS estimate of $17.34 and 7.0x our FY2029 estimate of $30.12. These multiples would be appropriate for a business in structural decline or facing existential competitive disruption. Allstate is neither: it is a top-four national insurer with 38 million personal lines policies, a strengthening balance sheet, improving underwriting margins, and a capital return programme that is among the most aggressive in the sector. For context, large-cap P&C insurers with comparable combined ratio profiles and premium growth rates have historically traded at 13-16x forward earnings through mid-cycle conditions. Allstate is not a premium-multiple business — regulatory exposure, catastrophe volatility, and competitive intensity justify a discount to the sector leaders — but the current discount is excessive. A re-rating from 12x to 13x on a growing EPS base generates significant price appreciation even without any fundamental upside to our base case forecasts. If management delivers on the low-90s combined ratio target and ASC approvals accelerate the growth trajectory, the upside case involves both EPS beats and multiple expansion simultaneously.

Risks

1. **Catastrophe Loss Volatility Can Overwhelm Underwriting Earnings in Any Single Year** Allstate's homeowners and commercial property exposure means that a severe hurricane, wildfire, or convective storm season can erase multiple quarters of underwriting profit in a single event. The company's catastrophe reinsurance programme provides some protection, but attachment points, coverage limits, and aggregate exposures mean that tail-risk events — particularly secondary perils like the California wildfires that have been structurally increasing in frequency and severity — can produce earnings outcomes dramatically below our base case. A year with $5+ billion of catastrophe losses would push the combined ratio well above 100 and could result in reported net income meaningfully below our FY2026 estimate of $4.4 billion, even if underlying ex-cat margins are tracking well. 2. **Regulatory Approval Delays Could Suppress Growth in Key States** Allstate's growth strategy is explicitly dependent on obtaining regulatory approval for rate increases and new product filings (particularly ASC) across states that have historically been adversarial. New York, California, New Jersey, and other large northeastern and coastal states are subject to political pressure on insurance affordability, and regulators in these jurisdictions have shown willingness to delay, reduce, or deny rate filings. If New York ASC approval is further deferred, or if multiple states move to impose rate rollbacks or affordability mandates in response to premium increases, the 7-9% annual premium growth assumption in our forecast could prove materially optimistic. The company reduced auto earned premium exposure in some states by non-renewing policies, and regulatory reversal of this risk management could force a different outcome. 3. **Loss Cost Inflation Re-Acceleration Could Compress Margins Before They Fully Normalise** Our combined ratio normalisation thesis rests on the assumption that auto severity inflation moderates from the 2022-2023 peaks. This is not guaranteed. Vehicle repair costs, medical care inflation, attorney involvement rates, and used vehicle prices remain elevated relative to pre-pandemic norms, and a re-acceleration — driven by tariffs on auto parts and imported vehicles, healthcare cost inflation, or increased litigation activity — would compress margins just as Allstate is accelerating new business growth. New business carries a first-year loss ratio penalty under normal conditions; if loss costs re-inflate simultaneously, the combined ratio could rise toward 100 rather than normalise toward the low 90s, materially impairing our FY2026-2027 earnings forecasts. 4. **Competitive Intensity From Progressive and GEICO Could Limit Pricing Power and Market Share Gains** Progressive is arguably the best-underwritten auto insurer in the United States, with superior telematics data (Snapshot), real-time pricing sophistication, and a cost structure that allows it to be price-competitive while still generating excellent returns. GEICO, under reinvestment following its 2022-2023 profitability crisis, is returning to the market with improved loss ratios and aggressive advertising. Allstate's Transformative Growth Initiative is designed to compete more effectively in the direct channel, but it is doing so against incumbents with significant head starts. If Progressive and GEICO price aggressively to recapture market share as the market re-enters growth mode, Allstate may find it difficult to grow policies-in-force at the rates assumed in our forecast without accepting adverse selection risk or accepting lower pricing margins. 5. **Investment Portfolio Duration and Credit Risk in a Volatile Rate Environment** Allstate's investment income growth thesis relies on reinvesting operating cash flow into a higher-yielding fixed income portfolio at current market rates. If interest rates decline materially — either due to a recession-driven Fed easing cycle or a broader risk-off environment — reinvestment yields will compress, and the investment income tailwind we have modelled will partially reverse. Additionally, the fixed income portfolio carries some credit risk; a stress scenario involving corporate credit spread widening or default cycle could produce mark-to-market losses and impair book value, with potential second-order effects on regulatory capital ratios and the company's ability to sustain its buyback programme at current levels. 6. **Execution Risk on the Transformative Growth Initiative and Technology Transition** The Transformative Growth Initiative requires the successful migration of policy administration, billing, and claims systems from legacy platforms to modern architecture across a multi-billion-dollar book of business. Technology transitions of this scale in insurance have a long history of cost overruns, timeline delays, and operational disruptions during the cutover period. Agent disruption, customer service degradation, or data integrity issues during platform migrations could lead to elevated lapse rates, agent attrition, or regulatory scrutiny. The cost savings from the programme are embedded in our expense ratio assumptions; material execution failure would delay or eliminate those savings while potentially imposing one-time remediation costs not captured in our base case forecasts.

📈 Price Targets